Eupraxia Pharmaceuticals EPRX
NASDAQ EPRX
$7.59 -0.14 (-1.81%)
At close: Oct 22, 2026 · 4:00 PM EDT

Eupraxia Pharmaceuticals (EPRX) Cash from Discontinued Operations (2023)

Updated

Analysis

Eupraxia Pharmaceuticals (EPRX) Cash from Discontinued Operations (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discont. Ops (Qtr)
1 Eli Lilly 1,144.36 Bn 1,112.95 Bn 19.71 Bn -
2 Johnson & Johnson 635.36 Bn 555.22 Bn 17.30 Bn -
3 AbbVie 502.79 Bn 475.90 Bn 12.70 Bn -
4 Merck 356.08 Bn 310.46 Bn 12.21 Bn -
5 Novartis Ag 300.87 Bn 264.86 Bn 11.24 Bn -
6 Astrazeneca 264.31 Bn 237.99 Bn 12.86 Bn -
7 Amgen 239.07 Bn 194.47 Bn 7.24 Bn -
8 Gilead Sciences 194.50 Bn 168.70 Bn 6.22 Bn -
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn -
10 Eupraxia Pharmaceuticals 286.89 Mn -155.18 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 -5.94 Mn
API Access

Eupraxia Pharmaceuticals Cash from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-discontinued-operations&ticker=EPRX&period=max&api_key=YOUR_API_KEY